BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

1919

524280

KOPRAN

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

KOPRAN LTD performance

Today’s low

Today’s high

₹ 188.99 ₹ 198.75
₹ 193.52

52 week low

52 week high

₹ 155.00 ₹ 369.70
₹ 193.52

Open Price

₹ 196.47

Prev. Close

₹ 196.47

Volume (Shares)

212446.00

Total traded value

₹ 411.12

Upper Circuit

₹ 235.76

Lower Circuit

₹ 157.17

info

KOPRAN LTD Share Price Update

As of the latest trading session, KOPRAN LTD share price is currently at ₹ 193.52, which is down by ₹ -2.94 from its previous closing. Today, the stock has fluctuated between ₹ 188.99 and ₹ 198.75. Over the past year, KOPRAN LTD has achieved a return of -24.38 %. In the last month alone, the return has been 3.76 %. Read More...

KOPRAN LTD fundamentals


  • Market cap (Cr)

    934.40

  • P/E Ratio (TTM)

    35.37

  • Beta

    1.42

  • Book Value / share

    89.35

  • Return on equity

    8.53%

  • EPS (TTM)

    5.56

  • Dividend yield

    1.52%

  • Net profit/quarter (Cr)

    8.60

info icon alternate text
  • Market cap (Cr)

    935.10

  • P/E Ratio (TTM)

    35.37

  • Beta

    1.30

  • Book Value / share

    89.35

  • Return on equity

    8.53%

  • EPS (TTM)

    5.56

  • Dividend yield

    1.52%

  • Net profit/quarter (Cr)

    8.60

info icon alternate text

KOPRAN LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 75.94
Operating Expense 66.15
Net Profit 8.60
Net Profit Margin (%) 11.32
Earnings Per Share (EPS) 1.78
EBITDA 14.21
Effective Tax Rate (%) 26.55
Particulars DEC 2024 (Values in Cr)
Revenue 71.94
Operating Expense 62.86
Net Profit 7.41
Net Profit Margin (%) 10.30
Earnings Per Share (EPS) 1.54
EBITDA 12.15
Effective Tax Rate (%) 24.61
Particulars SEP 2024 (Values in Cr)
Revenue 73.53
Operating Expense 65.89
Net Profit 6.60
Net Profit Margin (%) 8.97
Earnings Per Share (EPS) 1.37
EBITDA 10.81
Effective Tax Rate (%) 24.45
Particulars JUN 2024 (Values in Cr)
Revenue 49.61
Operating Expense 46.21
Net Profit 4.25
Net Profit Margin (%) 8.56
Earnings Per Share (EPS) 0.88
EBITDA 7.39
Effective Tax Rate (%) 23.04
Particulars MAR 2024 (Values in Cr)
Revenue 90.62
Operating Expense 78.22
Net Profit 15.31
Net Profit Margin (%) 16.89
Earnings Per Share (EPS) 3.18
EBITDA 23.49
Effective Tax Rate (%) 25.49
Particulars MAR 2025 (Values in Cr)
Revenue 271.01
Operating Expense 241.12
Net Profit 26.86
Net Profit Margin (%) 9.91
Earnings Per Share (EPS) 5.57
EBITDA 44.56
Effective Tax Rate (%) 24.97
Particulars MAR 2024 (Values in Cr)
Revenue 337.46
Operating Expense 309.65
Net Profit 34.64
Net Profit Margin (%) 10.26
Earnings Per Share (EPS) 7.18
EBITDA 53.64
Effective Tax Rate (%) 22.19
Particulars MAR 2023 (Values in Cr)
Revenue 273.09
Operating Expense 252.26
Net Profit 31.25
Net Profit Margin (%) 11.44
Earnings Per Share (EPS) 6.48
EBITDA 44.00
Effective Tax Rate (%) 15.33
Particulars MAR 2022 (Values in Cr)
Revenue 204.52
Operating Expense 196.38
Net Profit 11.74
Net Profit Margin (%) 5.74
Earnings Per Share (EPS) 2.65
EBITDA 23.43
Effective Tax Rate (%) 27.35
Particulars MAR 2021 (Values in Cr)
Revenue 222.83
Operating Expense 200.54
Net Profit 23.47
Net Profit Margin (%) 10.53
Earnings Per Share (EPS) 5.43
EBITDA 40.62
Effective Tax Rate (%) 28.21
Particulars MAR 2024 (Values in Cr)
Book Value / Share 101.90
ROE % 10.95
ROCE % 13.57
Total Debt to Total Equity 0.19
EBITDA Margin 14.48
Particulars MAR 2023 (Values in Cr)
Book Value / Share 91.11
ROE % 6.29
ROCE % 8.17
Total Debt to Total Equity 0.17
EBITDA Margin 9.96
Particulars MAR 2022 (Values in Cr)
Book Value / Share 88.40
ROE % 18.19
ROCE % 21.00
Total Debt to Total Equity 0.21
EBITDA Margin 20.52
Particulars MAR 2021 (Values in Cr)
Book Value / Share 56.65
ROE % 28.30
ROCE % 29.63
Total Debt to Total Equity 0.36
EBITDA Margin 20.29
Particulars MAR 2020 (Values in Cr)
Book Value / Share 43.86
ROE % 11.05
ROCE % 12.84
Total Debt to Total Equity 0.49
EBITDA Margin 13.01
Particulars MAR 2024 (Values in Cr)
Book Value / Share 86.47
ROE % 8.53
ROCE % 11.24
Total Debt to Total Equity 0.06
EBITDA Margin 15.90
Particulars MAR 2023 (Values in Cr)
Book Value / Share 82.05
ROE % 8.07
ROCE % 9.34
Total Debt to Total Equity 0.08
EBITDA Margin 16.11
Particulars MAR 2022 (Values in Cr)
Book Value / Share 78.56
ROE % 3.75
ROCE % 5.57
Total Debt to Total Equity 0.08
EBITDA Margin 11.46
Particulars MAR 2021 (Values in Cr)
Book Value / Share 57.07
ROE % 9.85
ROCE % 13.38
Total Debt to Total Equity 0.13
EBITDA Margin 18.23
Particulars MAR 2020 (Values in Cr)
Book Value / Share 53.10
ROE % 5.01
ROCE % 7.87
Total Debt to Total Equity 0.20
EBITDA Margin 14.03
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 14.19
Total Assets 743.24
Total Liabilities 743.24
Total Equity 491.24
Share Outstanding 48210605
Price to Book Ratio 2.99
Return on Assets (%) 6.85
Return on Capital (%) 8.63
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 12.57
Total Assets 649.69
Total Liabilities 649.69
Total Equity 439.24
Share Outstanding 48210605
Price to Book Ratio 1.35
Return on Assets (%) 4.19
Return on Capital (%) 5.29
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 57.13
Total Assets 610.88
Total Liabilities 610.88
Total Equity 426.16
Share Outstanding 48210605
Price to Book Ratio 3.58
Return on Assets (%) 9.99
Return on Capital (%) 12.19
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 6.89
Total Assets 439.38
Total Liabilities 439.38
Total Equity 245.03
Share Outstanding 43252602
Price to Book Ratio 1.84
Return on Assets (%) 14.02
Return on Capital (%) 19.92
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 4.74
Total Assets 371.44
Total Liabilities 371.44
Total Equity 189.68
Share Outstanding 43248900
Price to Book Ratio 0.48
Return on Assets (%) 5.65
Return on Capital (%) 7.85
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 7.42
Total Assets 510.87
Total Liabilities 510.87
Total Equity 416.86
Share Outstanding 48210605
Price to Book Ratio 2.99
Return on Assets (%) 6.77
Return on Capital (%) 7.88
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2.59
Total Assets 505.94
Total Liabilities 505.94
Total Equity 395.58
Share Outstanding 48210605
Price to Book Ratio 1.35
Return on Assets (%) 6.17
Return on Capital (%) 7.38
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.55
Total Assets 464.12
Total Liabilities 464.12
Total Equity 378.72
Share Outstanding 48210605
Price to Book Ratio 3.58
Return on Assets (%) 2.53
Return on Capital (%) 2.83
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.22
Total Assets 323.95
Total Liabilities 323.95
Total Equity 246.84
Share Outstanding 43252602
Price to Book Ratio 1.84
Return on Assets (%) 7.24
Return on Capital (%) 8.94
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.15
Total Assets 327.08
Total Liabilities 327.08
Total Equity 229.67
Share Outstanding 43252602
Price to Book Ratio 0.48
Return on Assets (%) 3.43
Return on Capital (%) 4.22
Particulars MAR 2024 (Values in Cr)
Net Income 67.54
Cash from Operations 57.58
Cash from Investing -43.55
Cash from Financing 0.98
Net change in Cash 0.69
Free Cash Flow 107.73
Particulars MAR 2023 (Values in Cr)
Net Income 36.06
Cash from Operations 46.80
Cash from Investing -12.65
Cash from Financing -19.84
Net change in Cash 1.52
Free Cash Flow 101.78
Particulars MAR 2022 (Values in Cr)
Net Income 81.78
Cash from Operations -15.20
Cash from Investing -84.41
Cash from Financing 122.82
Net change in Cash 4.93
Free Cash Flow 24.68
Particulars MAR 2021 (Values in Cr)
Net Income 83.33
Cash from Operations 75.98
Cash from Investing -25.27
Cash from Financing -34.57
Net change in Cash 0.10
Free Cash Flow 95.91
Particulars MAR 2020 (Values in Cr)
Net Income 28.83
Cash from Operations 38.70
Cash from Investing -12.51
Cash from Financing -18.06
Net change in Cash 0.41
Free Cash Flow 51.53
Particulars MAR 2024 (Values in Cr)
Net Income 44.51
Cash from Operations 44.79
Cash from Investing -6.26
Cash from Financing -24.08
Net change in Cash 4.61
Free Cash Flow 54.07
Particulars MAR 2023 (Values in Cr)
Net Income 36.91
Cash from Operations 23.18
Cash from Investing 10.04
Cash from Financing -26.13
Net change in Cash 0.78
Free Cash Flow 28.81
Particulars MAR 2022 (Values in Cr)
Net Income 16.16
Cash from Operations -34.19
Cash from Investing -100.26
Cash from Financing 137.98
Net change in Cash -0.07
Free Cash Flow -30.76
Particulars MAR 2021 (Values in Cr)
Net Income 32.70
Cash from Operations 54.18
Cash from Investing -8.50
Cash from Financing -40.14
Net change in Cash 0.11
Free Cash Flow 58.76
Particulars MAR 2020 (Values in Cr)
Net Income 15.73
Cash from Operations 13.84
Cash from Investing 0.62
Cash from Financing -10.59
Net change in Cash 0.00
Free Cash Flow 18.38
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 27.76 1.99 278.64 34.11 / 77.70
BLISS GVS PHARMA LTD 149.35 18.67 1.49 1573.70 101.00 / 184.95
CIPLA LTD 1505.40 23.06 3.89 121589.70 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 338.10 12.94 2.74 995.06 163.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 36.36 5.74 278.64 34.11 / 77.70
AMRUTAJAN HEALTH LTD 697.60 39.68 6.17 2016.81 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 10524.65 150.31 34.15 26311.63 6160.25 / 10653.05
BLISS GVS PHARMA LTD 149.35 22.80 1.48 1573.70 101.00 / 184.95

KOPRAN LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
193.52 -1.50 redarrow
red-green-graph indicator
8 Bearish
8 Bullish
  • 5 Days 197.20
  • 26 Days 191.30
  • 10 Days 194.90
  • 50 Days 189.80
  • 12 Days 194.20
  • 100 Days 195.00
  • 20 Days 192.20
  • 200 Days 210.50
197.36 PIVOT

First Support

194.67

First Resistance

199.16

Second Support

192.87

Second Resistance

201.85

Third Support

190.18

Third Resistance

203.65

RSI

56.88

ADX

40.67

MACD

2.85

Williams % R

-51.03

Commodity Channel Index (CCI)

86.98

Date

2025-06-13

Week

183044.00

Same Day

111083.00

Month

135691.00

1 Year

1.43

3 Year

1.33

Over 1 Month

3.76%

down

Over 1 Year

-24.38%

down

Over 3 Months

22.25%

down

Over 3 Years

-3.91%

down

Over 6 Months

-7.48%

down

Over 5 Years

42.48%

down

KOPRAN LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
54.45%
Promoter Holdings
44.42%
FII
1.12%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Oricon Enterprises Limited 6217183.0 (12.88%) Shareholding of Promoter and Promoter Group
Panorama Finvest Pvt Ltd 3800000.0 (7.87%) Shareholding of Promoter and Promoter Group
Sarvamangal Mercantile Co Ltd 2902951.0 (6.01%) Shareholding of Promoter and Promoter Group
United Shippers Ltd 2200000.0 (4.56%) Shareholding of Promoter and Promoter Group
Surendra Somani 1764750.0 (3.65%) Shareholding of Promoter and Promoter Group
Parijat Shipping And Finale Ltd. 911109.0 (1.89%) Shareholding of Promoter and Promoter Group
Viraj Russell Mehta 893590.0 (1.85%) Public Shareholding
Mridula Somani 788400.0 (1.63%) Shareholding of Promoter and Promoter Group
Laxminarayan Vyapaar P Ltd 751307.0 (1.56%) Public Shareholding
Madhuri Madhusudan Kela . 704593.0 (1.46%) Public Shareholding
Vandana Somani 688700.0 (1.43%) Shareholding of Promoter and Promoter Group
Varun Somani 534500.0 (1.11%) Shareholding of Promoter and Promoter Group
Surendra Somani 410075.0 (0.85%) Shareholding of Promoter and Promoter Group
Nupur Somani 270000.0 (0.56%) Shareholding of Promoter and Promoter Group
Susheel Somani 272000.0 (0.56%) Shareholding of Promoter and Promoter Group
Jaya Somani 258500.0 (0.54%) Shareholding of Promoter and Promoter Group
Mr Adarsh Somani 181250.0 (0.38%) Shareholding of Promoter and Promoter Group
Hridai Susheel Somani 116900.0 (0.24%) Shareholding of Promoter and Promoter Group
Suhrid Somani 93300.0 (0.19%) Shareholding of Promoter and Promoter Group
Somani Kumkum 35635.0 (0.07%) Shareholding of Promoter and Promoter Group
Kopran Lifestyle Limited 3950.0 (0.01%) Shareholding of Promoter and Promoter Group
G.claridge & Company Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Debonair Publication Pvt Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Hazarimall Somani 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

KOPRAN LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
07 Sep 2023 3.0 Final 08 Sep 2023 Equity shares
04 Aug 2022 3.0 Final 08 Aug 2022 Equity shares
05 Aug 2021 1.5 Final 09 Aug 2021 Equity shares
05 Nov 2020 1.5 Interim 07 Nov 2020 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
07 Sep 2023 3.0 Final 08 Sep 2023 Equity shares
04 Aug 2022 3.0 Final 08 Aug 2022 Equity shares
05 Aug 2021 1.5 Final 09 Aug 2021 Equity shares
05 Nov 2020 1.5 Interim 07 Nov 2020 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

KOPRAN LTD Share Price

Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility.

Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US.

Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran's high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce.

The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda.

The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002.

The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres.

The company has also increased its installed capacity of Tablets & Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos).

In Feb. 2001, Kopran tied up with E-Merck for co-marketing a new anti-inflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fast-moving non-steroid anti-inflammatory drugs (NSAID),has been launched in the international market. The Company also launched Cholestat (Atorvastatin - a cholesterol reducer) and further gave co-marketing rights for Atorvastatin to E-Merck (India).

The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004.

Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007.

The Company during the FY 2014-15 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015.

Parent organization Parijat
NSE symbol KOPRAN
Founded 1958
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Kopran Ltd?

Answer Field

Kopran Ltd share price is for NSE ₹ 193.52 & for BSE ₹ 194.20 as on Jun 16 2025 03:30 PM.

What is the Market Cap of Kopran Ltd Share?

Answer Field

The market cap of Kopran Ltd for NSE ₹ 932.97 & for BSE ₹ 936.24 as on Jun 16 2025 03:30 PM.

What is the 52 Week High and Low of Kopran Ltd?

Answer Field

The 52 Week High and Low of Kopran Ltd for NSE is ₹ 369.70 and ₹ 155.00 and for BSE is ₹ 369.20 and ₹ 157.00.

What is 1 year return for Kopran Ltd?

Answer Field

The 1 year returns on the stock has been -24.38%.

What is the P/E Ratio of Kopran Ltd Share?

Answer Field

As on Jun 16 2025 03:30 PM the price-to-earnings (PE) ratio for Kopran Ltd share is 35.37.

What is the PB ratio of Kopran Ltd Share?

Answer Field

As on Jun 16 2025 03:30 PM, the price-to-book (PB) ratio for Kopran Ltd share is 89.35.

How to Buy Kopran Ltd Share?

Answer Field

You can trade in Kopran Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Kopran Ltd Share on Bajaj Broking App?

Answer Field

To buy Kopran Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Kopran Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|